Jessica is the former Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley. During Jessica’s 40-year career of building Morgan Stanley’s biotechnology franchise, she has been responsible for $80Bn of capital raising and $85Bn of strategic transactions. Jessica was focused on company-building, examples of which include raising $38Bn for Moderna (4 offerings), $2.3Bn for BeOne Medicines (5 offerings) and $1Bn for Rhythm (6 offerings).  Strategic transactions include advising Agios in its Oncology Business sale to Servier, Galapagos in its $5.1Bn partnership with Gilead and Company Sales of Clementia, Cubist, Pharmasset and Elan. She was also involved in the creation of a new asset class involving royalty-backed debt  where over $30Bn has been raised.

Jessica has a BA in Commerce/Honours Economics from McGill University and an MBA from Harvard Business School.